Proton pump inhibitors in the elderly population

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue SUPPL. 1, 2002, Pages

  Whitaker, Mark ^a  

^a Didsbury Medical Centre   (United Kingdom)

Author keywords

Elderly; Gastro oesophageal reflux disease; Geriatric; Omeprazole; Proton pump inhibitors; Rabeprazole

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIAZEPAM; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LIDOCAINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROPRANOLOL; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ESOPHAGITIS; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT;

AGED; DRUG INTERACTIONS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS;

EID: 0036749543     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448-1456.
2. Ramirez FC. Diagnosis and treatment of gastroesophageal reflux disease in the elderly. Cleve Clin J Med 2000; 67:755-766.
3. Reynolds JC. Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. Am J Health Syst Pharm 1996; 53(Suppl. 3):5-12.
4. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995; 90:1053-1057.
5. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications. Am J Gastroenterol 2000; 95:368-373.
6. Collen MJ, Abdulian JD, Chen YK. Age does not affect basal gastric acid secretion in normal subjects or in patients with acid-peptic disease. Am J Gastroenterol 1994; 89:712-716.
7. Hodinka L. Improving the risk-benefit ratio of NSAID therapy in the elderly. Scand J Rheumatol 1991; 91(Suppl.):3-8.
8. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1):24-29.
9. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665-1670.
10. Pound SE, Heading RC. Diagnosis and treatment of dyspepsia in the elderly. Drugs Aging 1995; 7:347-354.
11. Tack J, Vantrappen G. The aging oesophagus. Gut 1997; 41:422-424.
12. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(Suppl. 9):491-505.
13. Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18:2-34.
14. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60:321-329.
15. James OF, Parry-Billings KS. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis. Age Ageing 1994; 23:121-126.
16. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13:179-186.
17. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ, for the European Rabeprazole Study Group. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. Dig Dis Sci 2000; 45:845-853.
18. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, for the European Rabeprazole Study Group. Double-blind comparison (correction of double-blind, placebo-controlled comparison) of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13:49-57.
19. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40:52-62.
20. Chutka DS, Evans JM, Fleming KC, Mikkelson KG. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70:685-693.
21. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7:10-18.
22. Le Jeunne C, Hugues FC. Drug interactions and the elderly. Therapie 1995; 50:247-252.
23. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12:485-494.
24. Spera AC, Humphries TJ, Merritt J, Laurent A. No dosage adjustment is required when rabeprazole sodium 20 mg is administered once daily to elderly patients. Gastroenterology 1997; 112:A908.
25. Keane WF, Swan SK, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 1999; 39:927-933.
26. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58:725-742.
27. Lew EA. Review article: pharmacokinetic concerns in the selection of antiulcer therapy. Aliment Pharmacol Ther 1999; 13(Suppl. 5):11-16.
28. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 1999; 21:691-701.
29. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38:243-270.
30. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991; 36:1665-1669.
31. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40:529-537.
32. Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug-drug interaction evaluation of rabeprazole sodium: a clean/expected slate? Gut 1996; 39(Suppl. 3):A47.
33. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3):18-26.
34. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58:155-164.